Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016.
"We are very pleased with the progress of Mirataz(TM) and Zimeta(TM), including the recently announced approval of the efficacy technical section for Mirataz," stated Richard Chin, M.D., President and CEO of KindredBio. "We are looking forward to the transiti
RelSci News & Alerts gets you:
- 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
- Competitive business intelligence through daily data updates
- Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox